Here’s what you need to know:
1. STELARA is manufactured by Janssen Biotech.
2. This treatment is the first biologic therapy for Crohn’s disease that targets interleukin-12 and interleukin-23 cytokines, which affect the body’s inflammatory and immune responses.
3. The initial STELARA dose is administered intravenously by a healthcare professional; subsequent doses are administered as subcutaneous injections every 8 weeks.
4. Janssen Biotech notes that STELARA is meant for patients who have already taken other medication, like immunomodulators or corticosteroids, that did not prove effective.
5. In clinical studies of STELARA, between 34 percent and 56 percent of patients experienced relief from their Crohn’s disease symptoms within 6 weeks after a one-time injection.
More articles on gastroenterology and endoscopy:
Kenneth Rainin Foundation awards $3M in IBD research grants: 5 notes
US Sen. Susan Collins honored for CRC screening initiatives: 3 notes
AGA awards research fellowship to Kimberly Agbo: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.